Author:
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Centers for Disease Control and Prevention, 2010. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 1–27.
-
2.
Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, Staples JE, Tomori O, Wilder-Smith A, Monath TP, 2011. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the informal WHO working group on geographic risk of yellow fever. Lancet Infect Dis 11: 622–632.
-
3.
Monath TP, Teuwen D, Cetron M, 2008. Yellow fever vaccine. Plotkin S, Orenstein W, Offit P, eds. Vaccines. Fifth edition. China: Elsevier, 959–1055.
-
4.
Monath TP, 1971. Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol 93: 122–129.
-
5.
Groot H, Riberiro RB, 1962. Neutralizing and hemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Organ 27: 699–707.
-
6.
Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, 1981. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895–900.
-
7.
Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT, 2000. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 38: 1823–1826.
-
8.
Beaty BJ, Calisher CH, Shope RE, 1995. Arboviruses. Lennette EH, Lennette DA, Lennette ET, eds. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. Seventh edition. Washington, DC: American Public Health Association, 189–212.
-
9.
Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R, 2008. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710–722.
-
10.
Darsie R, Ward R, 2005. Identification and Geographical Distribution of the Mosquitoes of North America, North of Mexico. Gainesville, FL: University Press of Florida.
-
11.
de Melo AB, da Silva M da P, Magalhães MC, Gonzales Gil LH, Freese de Carvalho EM, Braga-Neto UM, Bertani GR, Marques ET Jr, Cordeiro MT, 2011. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 85: 739–747.
-
12.
Nogueira R, Schatzmayr H, Miagostovich M, Cavalcanti S, de Carvalho R, 1992. Use of MAC-ELISA for evaluation of yellow fever vaccination. Rev Inst Med Trop Sao Paulo 34: 447–450.
-
13.
Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, Puttisri P, Hoke CH, 1989. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 40: 418–427.
-
14.
Lhuillier M, Sarthou J-L, 1983. Anti-yellow fever IgM in the diagnosis and epidemiological surveillance of yellow fever. Ann Virol 134E: 349–359.
-
15.
Kuno G, 2001. Persistence of arboviruses and antiviral antibodies in vertebrate hosts: its occurrence and impacts. Rev Med Virol 11: 165–190.
-
16.
Martínez MJ, Vilella A, Pumarola T, Roldan M, Sequera VG, Vera I, Hayes EB, 2011. Persistence of yellow fever vaccine RNA in urine. Vaccine 29: 3374–3376.
-
17.
Penna HA, Bittencourt A, 1943. Persistence of yellow fever virus in brains of monkeys immunized by cerebral inoculation. Science 97: 448–449.
-
18.
Gould EA, Buckley A, Cane PA, Higgs S, Cammack N, 1989. Use of a monoclonal antibody specific for wild-type yellow fever virus to identify a wild-type antigenic variant in 17D vaccine pools. J Gen Virol 70: 1889–1894.
-
19.
Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, García-Sastre A, Compans R, Pulendran B, 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543–547.
-
20.
Meurman OH, 1978. Persistence of immunoglobulin G and immunoglobulin M antibodies after postnatal rubella infection determined by solid-phase radioimmunoassay. J Clin Microbiol 7: 34–38.
-
21.
Edelman R, Schneider RJ, Vejjajiva A, Pornpibul R, Voodhikul P, 1976. Persistence of virus-specific IgM and clinical recovery after Japanese encephalitis. Am J Trop Med Hyg 25: 733–738.
-
22.
Malvy D, Ezzedine K, Mamani-Matsuda M, Autran B, Toluo H, Receveur MC, Pistone T, Rambert J, Moynet D, Mossalayi D, 2009. Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. BMC Infect Dis 9: 200–206.
-
23.
McAdam AJ, Farkash EA, Gewurz BE, Sharpe AH, 2000. B7 co-stimulation is critical for antibody class switching and CD8+ cytotoxic T-lymphocyte generation in the host response to vesicular stomatitis virus. J Virol 74: 203–208.
-
24.
Fuse S, Obar JJ, Bellfy S, Leung E, Zhang W, Usherwood EJ, 2006. CD80 and CD86 control antiviral CD8+ T-cell function and immune surveillance of murine gammaherpesvirus 68. J Virol 80: 9159–9170.
-
25.
Makino Y, Tadano M, Saito M, Maneekarn N, Sittisombut N, Sirisanthana V, Poneprasert B, Fukunaga T, 1994. Studies on serological cross-reaction in sequential flavivirus infections. Microbiol Immunol 38: 951–955.
-
26.
Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J, 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56: 159–167.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 39 | 39 | 14 |
| Full Text Views | 553 | 136 | 0 |
| PDF Downloads | 198 | 53 | 0 |
Detection of Anti-Yellow Fever Virus Immunoglobulin M Antibodies at 3–4 Years Following Yellow Fever Vaccination
Katherine B. Gibney
Katherine B. Gibney
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado; Epidemic Intelligence Service Program, CDC, Atlanta, Georgia; Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
Search for other papers by Katherine B. Gibney in
Current site
Google Scholar
PubMed
Search for other papers by Katherine B. Gibney in
Current site
Google Scholar
PubMed
Srilatha Edupuganti
Srilatha Edupuganti
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado; Epidemic Intelligence Service Program, CDC, Atlanta, Georgia; Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
Search for other papers by Srilatha Edupuganti in
Current site
Google Scholar
PubMed
Search for other papers by Srilatha Edupuganti in
Current site
Google Scholar
PubMed
Amanda J. Panella
Amanda J. Panella
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado; Epidemic Intelligence Service Program, CDC, Atlanta, Georgia; Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
Search for other papers by Amanda J. Panella in
Current site
Google Scholar
PubMed
Search for other papers by Amanda J. Panella in
Current site
Google Scholar
PubMed
Olga I. Kosoy
Olga I. Kosoy
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado; Epidemic Intelligence Service Program, CDC, Atlanta, Georgia; Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
Search for other papers by Olga I. Kosoy in
Current site
Google Scholar
PubMed
Search for other papers by Olga I. Kosoy in
Current site
Google Scholar
PubMed
Mark J. Delorey
Mark J. Delorey
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado; Epidemic Intelligence Service Program, CDC, Atlanta, Georgia; Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
Search for other papers by Mark J. Delorey in
Current site
Google Scholar
PubMed
Search for other papers by Mark J. Delorey in
Current site
Google Scholar
PubMed
Robert S. Lanciotti
Robert S. Lanciotti
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado; Epidemic Intelligence Service Program, CDC, Atlanta, Georgia; Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
Search for other papers by Robert S. Lanciotti in
Current site
Google Scholar
PubMed
Search for other papers by Robert S. Lanciotti in
Current site
Google Scholar
PubMed
Mark J. Mulligan
Mark J. Mulligan
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado; Epidemic Intelligence Service Program, CDC, Atlanta, Georgia; Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
Search for other papers by Mark J. Mulligan in
Current site
Google Scholar
PubMed
Search for other papers by Mark J. Mulligan in
Current site
Google Scholar
PubMed
Marc Fischer
Marc Fischer
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado; Epidemic Intelligence Service Program, CDC, Atlanta, Georgia; Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
Search for other papers by Marc Fischer in
Current site
Google Scholar
PubMed
Search for other papers by Marc Fischer in
Current site
Google Scholar
PubMed
J. Erin Staples
J. Erin Staples
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado; Epidemic Intelligence Service Program, CDC, Atlanta, Georgia; Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
Search for other papers by J. Erin Staples in
Current site
Google Scholar
PubMed
Search for other papers by J. Erin Staples in
Current site
Google Scholar
PubMed
The duration of anti-yellow fever (YF) virus immunoglobulin M (IgM) antibodies following YF vaccination is unknown, making it difficult to interpret positive IgM antibody results in previously vaccinated travelers. We evaluated the frequency and predictors of YF IgM antibody positivity 3–4 years following YF vaccination. Twenty-nine (73%) of 40 participants had YF IgM antibodies 3–4 years postvaccination. No demographic or exposure variables were predictive of YF IgM positivity. However, persons who were YF IgM positive at 3–4 years postvaccination had earlier onset viremia and higher neutralizing antibody geometric mean titers at 1 month and 3–4 years postvaccination compared with persons who were YF IgM negative. Detection of YF IgM antibodies several years postvaccination might reflect remote YF vaccination rather than recent YF vaccination or YF virus infection.
Author Notes
Financial support: Personnel at the Hope Clinic were partially funded through the Georgia Research Alliance.
Authors' addresses: Katherine Gibney, Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia, E-mail: Katherine.Gibney@monash.edu. Srilatha Edupuganti and Mark J. Mulligan, Decatur, GA, E-mails: edupug@emory.edu and mark.mulligan@emory.edu. Amanda J. Panella, Olga I. Kosoy, Mark J. Delorey, Robert S. Lanciotti, Marc Fischer, and J. Erin Staples, Fort Collins, CO, E-mails: apanella@cdc.gov, okosoy@cdc.gov, mdelorey@cdc.gov, rslanciotti@cdc.gov, mfischer@cdc.gov, and estaples@cdc.gov.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Centers for Disease Control and Prevention, 2010. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 1–27.
-
2.
Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, Staples JE, Tomori O, Wilder-Smith A, Monath TP, 2011. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the informal WHO working group on geographic risk of yellow fever. Lancet Infect Dis 11: 622–632.
-
3.
Monath TP, Teuwen D, Cetron M, 2008. Yellow fever vaccine. Plotkin S, Orenstein W, Offit P, eds. Vaccines. Fifth edition. China: Elsevier, 959–1055.
-
4.
Monath TP, 1971. Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol 93: 122–129.
-
5.
Groot H, Riberiro RB, 1962. Neutralizing and hemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Organ 27: 699–707.
-
6.
Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, 1981. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895–900.
-
7.
Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT, 2000. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 38: 1823–1826.
-
8.
Beaty BJ, Calisher CH, Shope RE, 1995. Arboviruses. Lennette EH, Lennette DA, Lennette ET, eds. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. Seventh edition. Washington, DC: American Public Health Association, 189–212.
-
9.
Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R, 2008. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710–722.
-
10.
Darsie R, Ward R, 2005. Identification and Geographical Distribution of the Mosquitoes of North America, North of Mexico. Gainesville, FL: University Press of Florida.
-
11.
de Melo AB, da Silva M da P, Magalhães MC, Gonzales Gil LH, Freese de Carvalho EM, Braga-Neto UM, Bertani GR, Marques ET Jr, Cordeiro MT, 2011. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 85: 739–747.
-
12.
Nogueira R, Schatzmayr H, Miagostovich M, Cavalcanti S, de Carvalho R, 1992. Use of MAC-ELISA for evaluation of yellow fever vaccination. Rev Inst Med Trop Sao Paulo 34: 447–450.
-
13.
Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, Puttisri P, Hoke CH, 1989. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 40: 418–427.
-
14.
Lhuillier M, Sarthou J-L, 1983. Anti-yellow fever IgM in the diagnosis and epidemiological surveillance of yellow fever. Ann Virol 134E: 349–359.
-
15.
Kuno G, 2001. Persistence of arboviruses and antiviral antibodies in vertebrate hosts: its occurrence and impacts. Rev Med Virol 11: 165–190.
-
16.
Martínez MJ, Vilella A, Pumarola T, Roldan M, Sequera VG, Vera I, Hayes EB, 2011. Persistence of yellow fever vaccine RNA in urine. Vaccine 29: 3374–3376.
-
17.
Penna HA, Bittencourt A, 1943. Persistence of yellow fever virus in brains of monkeys immunized by cerebral inoculation. Science 97: 448–449.
-
18.
Gould EA, Buckley A, Cane PA, Higgs S, Cammack N, 1989. Use of a monoclonal antibody specific for wild-type yellow fever virus to identify a wild-type antigenic variant in 17D vaccine pools. J Gen Virol 70: 1889–1894.
-
19.
Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, García-Sastre A, Compans R, Pulendran B, 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543–547.
-
20.
Meurman OH, 1978. Persistence of immunoglobulin G and immunoglobulin M antibodies after postnatal rubella infection determined by solid-phase radioimmunoassay. J Clin Microbiol 7: 34–38.
-
21.
Edelman R, Schneider RJ, Vejjajiva A, Pornpibul R, Voodhikul P, 1976. Persistence of virus-specific IgM and clinical recovery after Japanese encephalitis. Am J Trop Med Hyg 25: 733–738.
-
22.
Malvy D, Ezzedine K, Mamani-Matsuda M, Autran B, Toluo H, Receveur MC, Pistone T, Rambert J, Moynet D, Mossalayi D, 2009. Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. BMC Infect Dis 9: 200–206.
-
23.
McAdam AJ, Farkash EA, Gewurz BE, Sharpe AH, 2000. B7 co-stimulation is critical for antibody class switching and CD8+ cytotoxic T-lymphocyte generation in the host response to vesicular stomatitis virus. J Virol 74: 203–208.
-
24.
Fuse S, Obar JJ, Bellfy S, Leung E, Zhang W, Usherwood EJ, 2006. CD80 and CD86 control antiviral CD8+ T-cell function and immune surveillance of murine gammaherpesvirus 68. J Virol 80: 9159–9170.
-
25.
Makino Y, Tadano M, Saito M, Maneekarn N, Sittisombut N, Sirisanthana V, Poneprasert B, Fukunaga T, 1994. Studies on serological cross-reaction in sequential flavivirus infections. Microbiol Immunol 38: 951–955.
-
26.
Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J, 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56: 159–167.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 39 | 39 | 14 |
| Full Text Views | 553 | 136 | 0 |
| PDF Downloads | 198 | 53 | 0 |